Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients

Pneumonitis is a serious and unpredictable side-effect of treatment with methotrexate (MTX) that may become life-threatening. The clinical and histological features of nine cases of MTX pneumonitis are reported and the literature reviewed. The typical clinical symptoms include progressive shortness of breath and cough, often associated with fever. Hypoxaemia and tachypnoea are always present and crackles are frequently audible. Chest radiography reveals a diffuse interstitial or mixed interstitial and alveolar infiltrate, with a predilection for the lower lung fields. Pulmonary function tests show a restrictive pattern with diminished diffusion capacity. Lung biopsy reveals cellular interstitial infiltrates, granulomas or a diffuse alveolar damage pattern accompanied by perivascular inflammation. These clinical and pathological findings are not specific to MTX pneumonitis and can be seen with other drug-induced lung toxicities. It is important that all patients receiving methotrexate be educated concerning this potential adverse reaction and instructed to contact their physicians should significant new pulmonary symptoms develop while undergoing therapy. If methotrexate pneumonitis is suspected, methotrexate should be discontinued, supportive measures instituted and careful examination for different causes of respiratory distress conducted.

This article has been cited by other articles:

				J. J. Swigris, A. Fischer, J. Gilles, R. T. Meehan, and K. K. Brown Pulmonary and Thrombotic Manifestations of Systemic Lupus Erythematosus Chest, January 1, 2008; 133(1): 271 - 280. [Abstract] [Full Text] [PDF]

				K. Collins, H. Aspey, A. Todd, V. Saravanan, M. Rynne, and C. Kelly Methotrexate pneumonitis precipitated by switching from oral to parenteral administration Rheumatology, January 1, 2008; 47(1): 109 - 110. [Full Text] [PDF]

				V. Saravanan and C. Kelly Drug-related pulmonary problems in patients with rheumatoid arthritis Rheumatology, July 1, 2006; 45(7): 787 - 789. [Full Text] [PDF]

				A. J. Kinder, A. B. Hassell, J. Brand, A. Brownfield, M. Grove, and M. F. Shadforth The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions Rheumatology, January 1, 2005; 44(1): 61 - 66. [Abstract] [Full Text] [PDF]

				V. Saravanan and C. A. Kelly Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis Rheumatology, February 1, 2004; 43(2): 143 - 147. [Full Text] [PDF]

				A. J. K. Ostor, D. R. O'Gradaigh, and J. R. Jenner Methotrexate for rheumatoid arthritis: what should the patient be told? Rheumatology, December 1, 2003; 42(12): 1576 - 1578. [Full Text] [PDF]

				S. Abi-Nassif, E. J. Mark, R. B. Fogel, and R. K. Hallisey Jr Pegylated Interferon and Ribavirin-Induced Interstitial Pneumonitis With ARDS Chest, July 1, 2003; 124(1): 406 - 410. [Abstract] [Full Text] [PDF]

				P. A. Schlesinger and J. W. Leatherman Rheumatology Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1161 - 1165. [Full Text] [PDF]

				E. Azoulay, H. Attalah, A. Harf, B. Schlemmer, and C. Delclaux Granulocyte Colony-Stimulating Factor or Neutrophil-Induced Pulmonary Toxicity: Myth or Reality? : Systematic Review of Clinical Case Reports and Experimental Data Chest, November 1, 2001; 120(5): 1695 - 1701. [Full Text] [PDF]

				C. FUHRMAN, A. PARROT, M. WISLEZ, H. PRIGENT, V. BOUSSAUD, J.-F. BERNAUDIN, C. MAYAUD, and J. CADRANEL Spectrum of CD4 to CD8 T-Cell Ratios in Lymphocytic Alveolitis Associated with Methotrexate-induced Pneumonitis Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1186 - 1191. [Abstract] [Full Text] [PDF]

				Ph. Camus, P. Foucher, Ph. Bonniaud, and K. Ask Drug-induced infiltrative lung disease Eur. Respir. J., July 1, 2001; 18(32_suppl): 93S - 100s. [Abstract] [Full Text] [PDF]